Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On June 6, 2025, we reported on findings from a survey presented at the Revolutionizing Atopic Dermatitis (RAD) Conference 2025 that examined patient experience and preferences for atopic dermatitis (AD) treatment.
The study
The 31-question survey was made available to 43 eligible attendees at the 2024 National Eczema Association Eczema Expo. Among participants, 74% were aged 18 to 64 years, 21% were under 18, and 5% were aged 65 years or older. Notably, 40% (n = 16) of respondents reported a previous misdiagnosis of AD, and 28% (n = 12) had undergone skin biopsy to confirm their diagnosis.
The findings
Across all treatment types, the top 3 therapeutic attributes cited as most important by patients were itch control (70%), skin clearance (58%), and safety or side effect profile (50%).
More than 80% of participants indicated that they would want—or would consider—taking a molecular test to help identify the most effective targeted systemic therapy for their condition, suggesting strong patient interest in predictive tools to support shared decision-making.
Authors' comments
"A substantial number of AD patients experience delayed diagnosis. Itch was the most important symptom that respondents desired their medication to address. While topicals and systemic therapies can be effective, AD patients had a wide variety of treatment responses regardless of treatment modality, suggesting a need for a more personalized approach to treatment selection."
